Figure 4From: Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma High overall survival in chemo/immuno-naïve, stage M1A and partial responders to DAB/IL2. Median overall survival of these patients was determined using the Kaplan-Meier method and stratified based on prior treatment exposure (A), stage (M1A-C) (B) and response rate (C).Back to article page